Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

Basit Öğe Kaydı
dc.authoridErul, Enes/0000-0002-2487-2087
dc.authorwosidErul, Enes/AGJ-5340-2022
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorErul, Enes
dc.contributor.authorKaygusuz, Yunus
dc.contributor.authorAkagunduz, Baran
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorDe Luca, Raffaele
dc.contributor.authorRizzo, Alessandro
dc.date.accessioned2024-05-19T14:46:07Z
dc.date.available2024-05-19T14:46:07Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractPurposeImmune checkpoint inhibitors (ICIs) are related to various immune-related adverse events (irAEs). However, the knowledge is limited with rare irAEs like hearing loss. Therefore, we evaluated the characteristics, presentation, and treatment of ICI-related hearing loss by reviewing the individual patient data from the previous studies.MethodsWe conducted a systematic search of the Web of Science, PubMed, and Embase databases for studies published until 17 November 2022. The selected MeSH search terms were hearing loss OR hearing impairment OR ototoxicity OR vestibular toxicity OR audiovestibular toxicity AND immune checkpoint inhibitor OR immunotherapy.ResultsA total of 38 patients were included. Melanoma was the most frequent diagnosis (73.7%). The median time from ICI initiation to hearing loss development was 3 months. The hearing impairment was secondary to bilateral sensorineural hearing loss (SNHL) in 24 (68.6%) patients, and at least one other irAE accompanied the hearing loss in 24 patients. Hearing loss significantly improved in 45.7% of the patients. The overall response rate and disease control rate were 67.6% and 85.3%, respectively.ConclusionWe observed that most cases of ICI-related hearing loss were reversible, observed in patients with melanoma, accompanied by other irAEs, and associated with a high response rate to ICIs. With the expanded use of ICIs in the earlier treatment lines and adjuvant settings, the number of survivors with ICI-related hearing loss is expected to increase. Further research is needed to define the true prevalence of ICI-related hearing loss, optimal diagnosis, and management.en_US
dc.identifier.doi10.1007/s00520-023-08083-w
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue12en_US
dc.identifier.pmid37819422en_US
dc.identifier.scopus2-s2.0-85173709342en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1007/s00520-023-08083-w
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5448
dc.identifier.volume31en_US
dc.identifier.wosWOS:001081688000002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofSupportive Care In Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectOtotoxicityen_US
dc.subjectImmunotherapyen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectHearing Lossen_US
dc.subjectImmune-Related Adverse Eventen_US
dc.titleImmune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient dataen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu